Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 ...

Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - ...

Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...

At the low end, the drugs include $119,000 a year to treat certain rare genetic disorders. At the high end: a gene therapy ...

Australian rugby league is in mourning following the death of former Kangaroos prop Sam Backo. He was 64. The Indigenous prop ...

A “FIT and healthy” woman was left paralysed after suffering from headaches she thought were caused by “work stress”. Alicja ...

11-year-old DuJuan Broadus is the first U.S. patient to receive a MED-EL FLEX34 cochlear implant, designed for those with a larger cochlea. The new implant allows for a wider range of frequencies, ...

A ‘fit and healthy’ woman was left paralysed after headaches she thought were ‘work stress’ turned out to be signs of an ultra-rare brain disease. Alicja Faryniarz, 44, said she knew something ‘wasn’t ...

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

The importance of China as a growth market for pharma multinationals is underlined by the news that Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug under review for ...

A 'fit and healthy' woman was left paralysed after headaches she thought were 'work stress' turned out to be signs of an ...